Gemtuzumab ozogamicin (GO) is a CD33-directed antibody-drug conjugate approved for
the treatment of newly diagnosed (ND) and refractory/relapsed CD33-positive acute myeloid …

Increased understanding of the biology of neoplastic transformation is providing us with an
ever-increasing array of targets for intervention and drug development, and identification of …

The primary objective of this study was to investigate the tolerability, efficacy and
pharmacokinetic profile of gemtuzumab ozogamicin (GO) in patients with relapsed and/or …

Evidence regarding the efficacy of gemtuzumab ozogamicin (GO) addition to standard
induction chemotherapy in newly diagnosed acute myeloid leukaemia (AML) is conflicting …

Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …

Novel therapies with increased efficacy and decreased toxicity are desperately needed for
the treatment of acute myeloid leukaemia (AML). The anti CD33 immunoconjugate …

Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid
leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 …

Abstract On September 2, 2017, the US Food and Drug Administration approved
gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed …

Outcomes in acute myeloid leukemia (AML) remain unsatisfactory, and novel treatments are
urgently needed. One strategy explores antibodies and their drug conjugates, particularly …

Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized
anti-CD33 antibody (hP67. 6) linked to N-acetyl-calicheamicin 1, 2-dimethyl hydrazine …